This site is intended for Healthcare Professionals only.

NICE recommends Enhertu for advanced breast cancer


Share post:

The National Institute for Health and Care Excellence (NICE) has recommended Enhertu for people with advance breast cancer.

“There is not enough evidence yet to show how much longer people live with Enhertu compared with trastuzumab emtansine because the clinical trial is still ongoing. This means the cost-effectiveness estimates are highly uncertain and Enhertu cannot be recommended for routine use in the NHS,” said NICE.

The independent appraisal committee concluded that Enhertu could be cost-effective if further evidence from the ongoing trial and from NHS practice can show how much longer people live with treatment.

Helen Knight, director of medicines evaluation at NICE, said: “Today’s draft guidance is good news for people with this type of advanced breast cancer, who often experience severe and debilitating symptoms.

“It also means NICE has made positive recommendations in all 18 of its appraisals of breast cancer medicines since March 2018. These are all now available for clinicians to use in the treatment of thousands of NHS patients and demonstrate how NICE works successfully at the interface of health and care and the life sciences industry to enable early access to innovation.”



Please enter your comment!
Please enter your name here

Current Issue December 2023

Related articles

NPA raises question of accountability over authorising of pharmacy technicians

The government’s formal consultation on pharmacy supervision, which closes today (29 February), leaves important questions unanswered, the National...

Britain seeks ‘urgent reversal’ of fall in childhood vaccination rates

The government will on Thursday launch a drive to boost childhood vaccination rates, health authorities said, seeking an...

Health and care worker visas almost doubled in 2023

Britain almost doubled the number of visas awarded to foreign migrants coming to work in the health and...

Pfizer says its RSV shot is protective through a second year

Pfizer on Thursday said a single dose of its new respiratory syncytial virus (RSV) vaccine Abrysvo maintained its...